Immutep Ltd (IMM) reported that it will provide an update on the ongoing TACTI-mel Phase I clinical trial and the clinical development of eftilagimod alpha (“efti” or “IMP321”) in a global webcast, including a Q&A session
http://crweworld.com/article/news-provided-by-globenewswire/1031729/immutep-to-host-eftilagimod-alpha-clinical-development-update-global-webcast
Ann: Webcast details for update on eftilagimod alpha (IMP321), page-6
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.8¢ |
Change
0.003(0.82%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 30.5¢ | $496.3K | 1.593M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 298439 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 92970 | 11 |
View Market Depth
| Last trade - 14.17pm 17/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |